Other therapeutic modalities such as liver-targeted genome editing either as standard nuclease genome editing or base editing, have been used to inactivate PCSK9 and ANGPTL3 in non-human primates for the treatment of hypercholesterolemia and HTG [50] but whether these methods will be successfully applied to humans remains to be investigated. Here, PCSK9 is linked to familial hypercholesterolemia.